Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease
Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
24763757
PubMed Central
PMC3999268
DOI
10.1371/journal.pone.0096349
PII: PONE-D-13-52997
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- jaterní cirhóza komplikace patologie MeSH
- játra patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nealkoholová steatóza jater komplikace patologie MeSH
- obezita komplikace patologie MeSH
- obstrukční spánková apnoe etiologie MeSH
- rizikové faktory MeSH
- senioři MeSH
- stadia spánku MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: A high prevalence of obstructive sleep apnea syndrome (OSAS) has been reported in severely obese patients with nonalcoholic fatty liver disease (NAFLD), but few studies have evaluated OSAS in non-morbidly obese NAFLD patients. AIMS: To determine the prevalence of risk for OSAS with or without daytime sleepiness in non-morbidly obese patients with NAFLD and evaluate the association with the severity of liver damage. METHODS: We considered 159 consecutive patients with histological NAFLD and body mass index (BMI) <35 Kg/m2, and 80 controls without ultrasonographic steatosis matched for age, sex, and BMI. OSAS risk was determined by positivity for Berlin questionnaire (BQ), and daytime sleepiness by the Sleepness Epworth Scale (ESS). Liver damage was evaluated according to the NAFLD activity score. RESULTS: In NAFLD patients, BQ alone was positive in 39 (25%), ESS in 8 (5%), and both in 13 (8%, OSAS with sleepines); p = ns vs. controls without steatosis. In NAFLD patients at risk for OSAS with (but not in those without) sleepiness, we observed a higher prevalence of nonalcoholic steatohepatitis (NASH; 11/13, 85% vs. 72/146, 49%; p = 0.018), and of clinically significant fibrosis (stage>1; 9/13, 69% vs. 39/146, 27%; p = 0.003). At multivariate logistic regression analysis, OSAS with sleepiness was strongly associated with NASH and fibrosis>1 independently of known clinical risk factors such as age, gender, BMI, diabetes, and ALT levels (OR 7.1, 95% c.i. 1.7-51, p = 0.005 and OR 14.0, 95% c.i. 3.5-70, p = 0.0002, respectively). CONCLUSIONS: A proportion of NAFLD patients without severe obesity is at risk for OSAS with daytime sleepiness, which is associated with the severity of liver damage independently of body mass and other cofactors.
Zobrazit více v PubMed
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: 1844–1850. PubMed
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol 58: 593–608. PubMed
Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, et al. (2002) Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123: 134–140. PubMed
Dongiovanni P, Anstee QM, Valenti L (2013) Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment. Curr Pharm Des. PubMed PMC
Musso G, Gambino R, Cassader M, Pagano G (2012) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617–649. PubMed
Simon S, Collop N (2012) Latest advances in sleep medicine: obstructive sleep apnea. Chest 142: 1645–1651. PubMed
Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, et al. (2013) Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 14: 417–431. PubMed
Aurora RN, Punjabi NM (2013) Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association. Lancet Respir Med 1: 329–338. PubMed
Garvey JF, Taylor CT, McNicholas WT (2009) Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 33: 1195–1205. PubMed
Day CP (2006) From fat to inflammation. Gastroenterology 130: 207–210. PubMed
Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, et al. (2007) Chronic intermittent hypoxia predisposes to liver injury. Hepatology 45: 1007–1013. PubMed
Li J, Grigoryev DN, Ye SQ, Thorne L, Schwartz AR, et al. (2005) Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 99: 1643–1648. PubMed
Drager LF, Li J, Reinke C, Bevans-Fonti S, Jun JC, et al. (2011) Intermittent hypoxia exacerbates metabolic effects of diet-induced obesity. Obesity (Silver Spring) 19: 2167–2174. PubMed PMC
Tanne F, Gagnadoux F, Chazouilleres O, Fleury B, Wendum D, et al. (2005) Chronic liver injury during obstructive sleep apnea. Hepatology 41: 1290–1296. PubMed
Tatsumi K, Saibara T (2005) Effects of obstructive sleep apnea syndrome on hepatic steatosis and nonalcoholic steatohepatitis. Hepatol Res 33: 100–104. PubMed
Turkay C, Ozol D, Kasapoglu B, Kirbas I, Yildirim Z, et al. (2012) Influence of obstructive sleep apnea on fatty liver disease: role of chronic intermittent hypoxia. Respir Care 57: 244–249. PubMed
Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, et al. (2005) Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci 50: 2338–2343. PubMed
Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP (1999) Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 131: 485–491. PubMed
Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540–545. PubMed
Johns MW (2000) Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 9: 5–11. PubMed
Hiestand DM, Britz P, Goldman M, Phillips B (2006) Prevalence of symptoms and risk of sleep apnea in the US population: Results from the national sleep foundation sleep in America 2005 poll. Chest 130: 780–786. PubMed
Gus M, Goncalves SC, Martinez D, de Abreu Silva EO, Moreira LB, et al. (2008) Risk for Obstructive Sleep Apnea by Berlin Questionnaire, but not daytime sleepiness, is associated with resistant hypertension: a case-control study. Am J Hypertens 21: 832–835. PubMed
Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, et al. (2010) Homozygosity for the PNPLA3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51: 1209–1217. PubMed
Mishra P, Younossi ZM (2007) Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 102: 2716–2717. PubMed
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, et al. (2000) Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23: 57–63. PubMed
Supplement 1. American Diabetes Association: clinical practice recommendations 2000. Diabetes Care 23 Suppl 1S1–116. PubMed
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143–3421. PubMed
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321. PubMed
Rosselli M, MacNaughtan J, Jalan R, Pinzani M (2013) Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 62: 1234–1241. PubMed
Kallwitz ER, Herdegen J, Madura J, Jakate S, Cotler SJ (2007) Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol 41: 918–921. PubMed
Mishra P, Nugent C, Afendy A, Bai C, Bhatia P, et al. (2008) Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 28: 1080–1086. PubMed
Aron-Wisnewsky J, Minville C, Tordjman J, Levy P, Bouillot JL, et al. (2012) Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 56: 225–233. PubMed
Newton JL, Jones DE, Henderson E, Kane L, Wilton K, et al. (2008) Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 57: 807–813. PubMed
Newton JL (2010) Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis 28: 214–219. PubMed
Bersagliere A, Raduazzo ID, Nardi M, Schiff S, Gatta A, et al. (2012) Induced hyperammonemia may compromise the ability to generate restful sleep in patients with cirrhosis. Hepatology 55: 869–878. PubMed
Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, et al. (2000) Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132: 112–117. PubMed
Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, et al. (2008) The risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48: 792–798. PubMed
Chin K, Nakamura T, Takahashi K, Sumi K, Ogawa Y, et al. (2003) Effects of obstructive sleep apnea syndrome on serum aminotransferase levels in obese patients. Am J Med 114: 370–376. PubMed
Kohler M, Pepperell JC, Davies RJ, Stradling JR (2009) Continuous positive airway pressure and liver enzymes in obstructive sleep apnoea: data from a randomized controlled trial. Respiration 78: 141–146. PubMed